Aspen Neuroscience at a glance
As of- [1] Total funding (reported): SEC, October 22, 2026
Is this your company? Get featured or correct your listing →
Recent changes
- Oct 22, 2026Oct 22, 2026IPO an undisclosed amount SEC
- Oct 22, 2026Oct 22, 2026First reported total funding: $347M SEC
- Oct 22, 2026Oct 22, 2026Aspen Neuroscience Plans Nasdaq IPO After $347M Raised Pulse story
Debt, IPO & other events
not counted in equity raised| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Oct 22, 2026 | ipo | — | — | ARCH Venture PartnersLeadunverifiedOrbiMed AdvisorsLeadunverifiedFrazier Life SciencesLeadunverifiedMedical Excellence CapitalKite (Gilead) | SEC |
Investors
Latest Pulse
- Oct 22, 2026Lycia Prices IPO at $18.00, Starts Trading as LYCALycia Therapeutics priced its upsized IPO above expectations and began trading on Nasdaq, raising about $317.5 million for its clinical-stage pipeline.→
- Oct 22, 2026Aspen Neuroscience Plans Nasdaq IPO After $347M RaisedAspen Neuroscience, a clinical-stage cell-therapy biotech backed by ARCH and OrbiMed, amended its IPO filing to list on Nasdaq under ASPE after raising about $347 million since 2018.→
Coverage Timeline
newest firstAll Coverage
Value Add Research
Related Companies
Aspen Neuroscience FAQ
How much has Aspen Neuroscience raised?
Aspen Neuroscience has raised $347M in total funding, according to SEC (October 22, 2026).
Sources & methodologyshow
Where these figures come from
- SECprimary source2 facts
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.